Therapy

• tenecteplase ^a
• reteplase ^a

Why?

• Patients who receive reteplase and tenecteplase compared with alteplase are not less likely to die or have a stroke. ^a

Note

• Bolus doses of thrombolytic agents slightly increase the risk of intracranial haemorrhage compared with infusions, without reducing death or myocardial infarction.  ^a  

Bolus thrombolysis slightly increases the risk of intracranial haemorrhage

Patient	Treatment	Comparison	Outcome	CER	OR (95% CI)	NNT (95% CI)
acute coronary syndrome with ST elevation a	bolus of thrombolysis	infusion of thrombolysis	intracranial haemorrhage at 30 days	0.61%	1.25 (1.08 to 1.45)	660 (370 to 2100)